Brad Hirsch

Brad Hirsch is a healthcare executive and medical oncologist with extensive experience in clinical research, technology, and entrepreneurship.12 He currently serves as the Head of Product & Implementation at Verily, an Alphabet company focused on healthcare technology solutions.3

Career Highlights

Verily and SignalPath: Brad joined Verily in September 2021 when the company acquired SignalPath, a clinical trials technology solution he co-founded and led as CEO.12 He initially served as CEO of SignalPath within Verily before transitioning to his current role as Head of Product & Implementation in January 2023.1

Previous Roles: Prior to founding SignalPath, Brad held several notable positions:

• Senior Medical Director at Flatiron Health
• Assistant Professor at Duke University and Director of Informatics & Learning Labs at Duke Center for Learning Health Care
• Medical Oncologist at Texas Oncology1

Education and Expertise

Brad's educational background combines medicine and business:

• MD from UT Southwestern Medical Center
• MBA from Duke University's Fuqua School of Business
• BA from the University of Pennsylvania12

His expertise spans clinical oncology, health informatics, and clinical research technology. Brad has been a principal investigator on trials, which informs his approach to reimagining clinical research.2

Recent Developments

As of January 29, 2024, Brad announced that he would be moving on from his role at SignalPath/Verily.4 Subsequently, in September 2024, he co-founded Highlander Health with Amy Abernethy, another former Verily executive. This new venture aims to optimize clinical trials and improve data-driven clinical research.56